SCHEMBL2900359

SCHEMBL2900359

COc1cc(OC)nc(-n2c(=S)[nH]c3cc(C(=O)NCc4ccncc4)ccc3c2=O)n1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.60
▸ MEN1 O00255 5/20 0.60
▸ USP2 O75604 1/20 0.56
▸ LMNA P02545 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ ALDH1A1 P00352 8/20 0.52
▸ MAPT P10636 6/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.48
▸ GLA P06280 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ RXFP1 Q9HBX9 3/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583785 0.91 USP2 (0.58) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2895423 0.90 USP2 (0.57) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2902339 0.89 USP2 (0.56) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2897583 0.88 USP2 (0.55) KMT2AMEN1USP2LMNAPOLB
SCHEMBL13786378 0.88 USP2 (0.55) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2895356 0.88 USP2 (0.54) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2902443 0.87 USP2 (0.54) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2897673 0.86 MEN1 (0.57) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2915582 0.86 MEN1 (0.57) KMT2AMEN1USP2LMNAPOLB
SCHEMBL2897918 0.86 ALDH1A1 (0.53) KMT2AMEN1USP2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 KMT2A 395/4885MEN1 4104/4885USP2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback